Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Breast Neoplasms 15Triple Negative Breast Neoplasms 5Ovarian Neoplasms 4Prostatic Neoplasms 3Melanoma 3Lymphoma 3Lung Neoplasms 3Endometrial Neoplasms 3Uterine Cervical Neoplasms 2Multiple Myeloma 2Locally Advanced (Inoperable) or Metastatic Breast Cancer 2Leukemia 2Hematologic Neoplasms 2Healthy Participants 2Disease Progression 2Carcinoma, Non-Small-Cell Lung 2Uterine Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Rectal Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Moderate Hepatic Impairment 1

Interventions

Magnetic Resonance Spectroscopy 7lutetium Lu 177 dotatate 6Specimen Handling 5Bevacizumab 4gallium Ga 68 dotatate 3abemaciclib 3Radiosurgery 3Proton Therapy 3Nivolumab 3pembrolizumab 2Surveys and Questionnaires 2Sunitinib 2Protons 2Observation 2ONC206 2Ipilimumab 2Hydroxyurea 2Ga(III)-DOTATOC 2Everolimus 2Elasticity Imaging Techniques 2CTLA-4 Antigen 2ribociclib 1regorafenib 1olaparib 1neratinib 1dexamethasone acetate 1dexamethasone 21-phosphate 1capivasertib 1cabozantinib 1brigatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Meningioma × capivasertib × 1 year × Clear all
NCT02523014 2026-06-02

Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

Alliance for Clinical Trials in Oncology

Phase 2 Recruiting
124 enrolled
CNS

Meningioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡